Genetically engineered natural killer (NK) cell immunotherapy for children poor risk b-cell (CD20+) leukemia and lymphoma (L/L).

被引：0
|
作者：
Chu, Yaya [1 ]
Ayello, Janet [1 ]
Hochberg, Jessica [1 ]
Van de Ven, Carmella [1 ]
Murphy, James [1 ]
Cairo, Mitchell S. [1 ]
机构：
[1] New York Med Coll, Valhalla, NY 10595 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13022
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Immunotherapy of B-Cell Lymphoma with an Engineered Bispecific Antibody Targeting CD19 and CD5
    Lttgau, Sandra
    Deppe, Dorothee
    Meyer, Saskia
    Fertig, Regina
    Panjideh, Hossein
    Lipp, Martin
    Schmetzer, Oliver
    Pezzutto, Antonio
    Breitling, Frank
    Moldenhauer, Gerhard
    ANTIBODIES, 2013, 2 (02): : 338 - 352
  • [22] A Study of Rituximab and Ifosfamide, Carboplatin, and Etoposide Chemotherapy in Children with Recurrent/Refractory B-Cell (CD20+) Non-Hodgkin Lymphoma and Mature B-Cell Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group
    Griffin, Timothy C.
    Weitzman, Sheila
    Weinstein, Howard
    Chang, Myron
    Cairo, Mitchell
    Hutchison, Robert
    Shiramizu, Bruce
    Wiley, Joseph
    Woods, Deborah
    Barnich, Margaret
    Gross, Thomas G.
    PEDIATRIC BLOOD & CANCER, 2009, 52 (02) : 177 - 181
  • [23] First-line therapy of CD20+ diffuse large B-cell lymphoma: facts and open questions
    Brusamolino, Ercole
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (09): : 1194 - 1198
  • [24] L-asparaginase for adult CD20 positive B-cell precursor acute lymphoblastic leukemia
    Maury, Sebastien
    Huguet, Francoise
    Ifrah, Norbert
    Dombret, Herve
    Bene, Marie-Christine
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (06): : 1042 - 1042
  • [25] REDUCED BURDEN OF ONCOLOGIC THERAPY IN ADVANCED B-CELL LYMPHOMA IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS WITH CD20+MATURE B-CELL LYMPHOMA
    Hochberg, Jessica
    Barth, Matthew
    Goldman, Stanton
    Klejmont, Liana
    Harrison, Lauren
    Shi, Quihi
    Perkins, Sherrie
    Miles, Rodney
    Shiramizu, Bruce
    Cairo, Mitchell
    PEDIATRIC BLOOD & CANCER, 2018, 65
  • [26] Blastic natural killer-cell leukemia/lymphoma (NKL/L): A clinicopathologic study of 3 cases
    DiGiuseppe, JA
    Louie, DC
    Williams, JE
    Miller, DT
    Griffin, CA
    Mann, RB
    Borowitz, MJ
    LABORATORY INVESTIGATION, 1997, 76 (01) : 718 - 718
  • [27] In Vivo Eradication of a Rituximab-Resistant Human CD20+ B Cell Lymphoma by Rituximab-CpG Oligodeoxynucleotide Conjugate Is Mediated by Natural Killer Cells and Complement
    Betting, David J.
    Kafi, Kamran
    Yamada, Reiko E.
    Steward, Kristopher K.
    Olafsen, Tove
    Wu, Anna M.
    van Rooijen, Nico
    Timmerman, John M.
    BLOOD, 2009, 114 (22) : 302 - 302
  • [28] Significantly targeting rituximab resistant B-cell lymphoma (BL) by anti-CD20 chimeric antigen receptor (CAR) modified expanded natural killer (NK) cells.
    Chu, Yaya
    Ayello, Janet
    Yahr, Ashlin
    Katz, Jared
    Lo, Lowrence
    Flowers, Allyson
    Cairo, Mitchell S.
    CANCER RESEARCH, 2013, 73
  • [29] CD22-targeted glyco-engineered natural killer cells offer a further treatment option for B-cell acute lymphoblastic leukemia
    Jin, Xin
    Sun, Rui
    Li, Zhu
    Wang, Xianwu
    Xiong, Xia
    Lu, Wenyi
    Lyu, Hairong
    Xiao, Xia
    Tian, Yunpeng
    Zhang, Hongkai
    Fang, Zhihong
    Wang, Luqiao
    Zhao, Mingfeng
    HAEMATOLOGICA, 2024, 109 (09) : 3004 - 3008
  • [30] Reduced burden of oncologic therapy in advanced B-cell lymphoma (REBOOT ABLY) in children, adolescents and young adults with CD20+mature B-cell lymphoma
    Goldman, S.
    Hochberg, J.
    Harrison, L.
    Kallis, M.
    Barth, M.
    Galardy, P.
    Miles, R.
    Sanger, W.
    Shiramizu, B.
    Lim, M.
    Perkins, S. L.
    Hermiston, M.
    Frazer, J. K.
    Cairo, M. S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 159 : 60 - 60
12345